Article
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Science translational medicine - 6 Jul 2011
Chmielecki Juliann, Foo Jasmine, Oxnard Geoffrey R, Hutchinson Katherine, Ohashi Kadoaki, Somwar Romel, Wang Lu, Amato Katherine R, Arcila Maria, Sos Martin L, Socci Nicholas D, Viale Agnes, de Stanchina Elisa, Ginsberg Michelle S, Thomas Roman K, Kris Mark G, Inoue Akira, Ladanyi Marc, Miller Vincent A, Michor Franziska, Pao William
Abstract excerpt
Non-small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Unfortunately, all patients treated with these drugs will acquire resistance, most commonly as a result of a secondary mutation within EGFR (T790M). Because both drugs were developed to target wild-type EGFR, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.